Wonderful first day European Association of Urology (EAU) #EAU24 in #Paris my personal take home messages from #bladdercancer European Urology Oncology Association Française d'Urologie - AFU

🚨 Breaking results 🚨 PRIME Trial UCL study presented at #EAU24 European Association of Urology (EAU). This 🌍 multicentre trial (n=555, 22 sites) showed that biparametric MRI without contrast is non-inferior 2 multiparametric MRI & should be the new standard for prostate cancer diagnosis if image quality is good

Proud to be a part of this wonderful ESU course about complications in laparoscopic and robotic urology during the EAU annual meeting in Paris. Honoured to be among Bernardo Rocco Abdullah Erdem Canda Thank you Maria Chiara Sighinolfi Simone Assumma. European Association of Urology (EAU) European School of Urology (EAU ESU)

PSMA has 80-90% NPV but poor sensitivity for pelvic lymph nodes - cannot replace staging extended PLND. Plus new data that ePLND reduces distant metastases -Jochen Walz #apccc24

⁦Bernardo Rocco⁩ telemoderation and guiding young promising surgeons using PBP metrics #nextgen ⁦OLV Aalst Urology⁩ ⁦Orsi Academy⁩ ⁦Ruben De Groote⁩ ⁦𝙍𝙞𝙘𝙘𝙖𝙧𝙙𝙤 𝘽𝙚𝙧𝙩𝙤𝙡𝙤 MD PhD⁩

“Together we have realised something very important.” Hein Van Poppel of European Association of Urology (EAU) was one of the founders of Europa Uomo – and on its 20th anniversary, he tells why the European #prostatecancer patients’ coalition has been so important to him. bit.ly/4aNlRD5

The best use of PARP inhibitors in mCRPC. Presented by Joaquin Mateo Vall d’Hebron Institute of Oncology (VHIO) Vall d'Hebron. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology. > bit.ly/3WhQ6xl Advanced Prostate Cancer Consensus Conference

Debate: how to best manage a fit patient with high-risk localised and locally advanced #prostatecancer? Presented by Jason Efstathiou, MD, DPhil, Harvard Medical School. #APCCC24 Written coverage by Rashid K. Sayyid University of Toronto. > bit.ly/3y6wIJC Advanced Prostate Cancer Consensus Conference.

PSMA PET/CT-detected mesorectal nodal metastasis in biochemically recurrent #ProstateCancer patients. Presentation by Rashid K. Sayyid University of Toronto. #AUA24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3UKSADv Amer. Urol. Assn.

Correlation of intraprostatic SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy. Presentation by Felix Preisser, MD UKE Hamburg. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/3QyFwyC

#CrossfirePanel: Controversies in #urology: Pre-op 3D models help improve surgical outcomes in renal cancer surgery. Ahmed Ghazi Alberto Martini Ketan K. Badani MD Arieh Shalhav and Brian Schuch. #AUA24 written coverage by Brandon Camp > bit.ly/4afC96M

Non c'è nessun posto dove nasconderti quando a perseguitati è la tua mente.

Great summary of genes on prostate cancer panels and current implications for #prostatecancer risk & treatment, as well as for hereditary cancer risk in families -Veda Giri at BRCA Research & Cure Alliance (CureBRCA) meeting

Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study by Chiara Casadei et al Read the full article here: eu-openscience.europeanurology.com/article/S2666-… #UroSoMe #Medtwitter #ProstateCancer #PCa

Practical approach to #GeneticTesting and treatment selection in #ProstateCancer. Presentation by David VanderWeele MD PhD Lurie Cancer Center. #ASCO24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/4aH3yOZ Northwestern Feinberg School of Medicine

Independent blinded validation of an AI-based digital histology classifier (PATHOMIQ_PRAD score) for BCR and mets risk prediction #ASCO24 Magdalena Fay, MD MS UroToday.com Cleveland Clinic Urology ⚡️n=263 RP (mF/U 50 mo) -> 65 BCR -> 14 distant mets ⚡️PATHOMIQ_PRAD score ⬆️ vs ⬇️: assoc with BCRFS

Probably an outdated discussion, but our randomized trial Open versus RARP was finally published. A Herculean effort that started 10 years ago

📢 Nuova possibilità di cura per pazienti affetti da tumore vescicale muscolo infiltrante eleggibili a chirurgia. Prima evidenza di come l'immunoterapia ⬆️ la sopravvivenza insieme alla chemioterapia! ✅️ astrazeneca.com/media-centre/p… associazionepalinuro

Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent PCs Death—Results from the Norwegian Prostate Cancer Consortium by Johan Bjerner et al. Read the full article here: buff.ly/45B4T9m Ola Bratt Kirsti Aas Andrew Vickers Sigrid Carlsson

Fluorine-18 PSMA-1007 PET/CT vs Multiparametric MRI for Prostate Cancer Staging 🔵Tumor Stage: 18F-PSMA-1007 PET/CT superior (45% vs 28%) 🔵Dominant Nodule: PET/CT better (94% vs 83%) 🔵Laterality: PET/CT better (64% vs 44%) 🔵ECE: PET/CT better (75% vs 63%) 🔵SVI: Not